Abstract

PurposeOur goal in this study was to find correlations between breast cancer metabolites and conventional quantitative imaging parameters using high-resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) and to find breast cancer subgroups that show high correlations between metabolites and imaging parameters.Materials and methodsBetween August 2010 and December 2013, we included 53 female patients (mean age 49.6 years; age range 32–75 years) with a total of 53 breast lesions assessed by the Breast Imaging Reporting and Data System. They were enrolled under the following criteria: breast lesions larger than 1 cm in diameter which 1) were suspicious for malignancy on mammography or ultrasound (US), 2) were pathologically confirmed to be breast cancer with US-guided core-needle biopsy (CNB) 3) underwent 3 Tesla MRI with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) and positron emission tomography-computed tomography (PET-CT), and 4) had an attainable immunohistochemistry profile from CNB. We acquired spectral data by HR-MAS MRS with CNB specimens and expressed the data as relative metabolite concentrations. We compared the metabolites with the signal enhancement ratio (SER), maximum standardized FDG uptake value (SUV max), apparent diffusion coefficient (ADC), and histopathologic prognostic factors for correlation. We calculated Spearman correlations and performed a partial least squares-discriminant analysis (PLS-DA) to further classify patient groups into subgroups to find correlation differences between HR-MAS spectroscopic values and conventional imaging parameters.ResultsIn a multivariate analysis, the PLS-DA models built with HR-MAS MRS metabolic profiles showed visible discrimination between high and low SER, SUV, and ADC. In luminal subtype breast cancer, compared to all cases, high SER, ADV, and SUV were more closely clustered by visual assessment. Multiple metabolites were correlated with SER and SUV in all cases. Multiple metabolites showed correlations with SER and SUV in the ER positive, HER2 negative, and Ki-67 negative groups.ConclusionHigh levels of PC, choline, and glycine acquired from HR-MAS MRS using CNB specimens were noted in the high SER group via DCE MRI and the high SUV group via PET-CT, with significant correlations between choline and SER and between PC and SUV. Further studies should investigate whether HR-MAS MRS using CNB specimens can provide similar or more prognostic information than conventional quantitative imaging parameters.

Highlights

  • Breast cancer encompasses a heterogeneous group of diseases with various histological differentiations, clinical courses, and responses to treatment

  • The partial least squares-discriminant analysis (PLS-DA) models built with High-resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) metabolic profiles showed visible discrimination between high and low signal enhancement ratio (SER), standardized FDG uptake value (SUV), and apparent diffusion coefficient (ADC)

  • High levels of PC, choline, and glycine acquired from HR-MAS MRS using core-needle biopsy (CNB) specimens were noted in the high SER group via Dynamic contrast-enhanced (DCE) MRI and the high SUV group via positron emission tomography-computed tomography (PET-CT), with significant correlations between choline and SER and between PC and SUV

Read more

Summary

Introduction

Breast cancer encompasses a heterogeneous group of diseases with various histological differentiations, clinical courses, and responses to treatment. In addition to traditional parameters such as tumor size, tumor grade, and lymph node status, several molecular markers are used to classify breast cancers into subgroups and to predict clinical outcomes [1, 2]. Recent studies using HR-MAS MRS have found different concentrations of choline-containing compounds in breast cancer tissue and these different distributions have been correlated with clinicopathological parameters that predict tumor aggressiveness [7,8,9]. A recent study suggested that HR-MAS MRS using core-needle biopsy (CNB) specimens could predict tumor aggressiveness prior to surgery because several molecular markers significantly correlated with histologic prognostic factors [4]

Objectives
Methods
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.